Compare HCA Health Inc (HCA) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs T Rowe Price Group Inc — how do they compare? HCA Health Inc trades at $371.75 (market cap $82.17B), while T Rowe Price Group Inc trades at $117.54 (market cap $25.14B). The key difference: HCA Health Inc is far larger — about 3.3× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays the higher dividend (4.43%). Which is the better fit depends on your goals.
| HCA | TROW | |
|---|---|---|
Market Cap | $82.17B | $25.14B |
Sector | Health | Financials |
52-Week High | $545.13 | $120.16 |
52-Week Low | $334.32 | $86.19 |
Enterprise Value | $131.08B | $21.85B |
Dividend Yield | 0.84% | 4.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $370.74, down 0.12% on the day, with a bearish technical signal but strong fundamentals including consistent earnings beats and revenue growth to $75.6 billion in 2025. The stock faces headwinds from lowered 2026 guidance and negative news flow, but maintains a solid valuation with a P/E of 12.79 and positive analyst consensus.
The outlook is mixed: attractive valuation and operational strength support upside to the $469.40 price target, but near-term risks from payer mix shifts and legal investigations warrant caution. Long-term growth drivers include capacity expansion and medical advancements, though investor sentiment is currently pressured.
T. Rowe Price (TROW) trades at $116.345, down 0.86% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings that beat expectations, with revenue growth from $7.1B in 2024 to $7.3B in 2025 and a net income margin of 28.28%. Recent news highlights the launch of an active crypto ETF and AUM reaching $1.89 trillion in June 2026.
The outlook for TROW is mixed; valuation ratios like a P/E of 12.59 suggest potential undervaluation, but analyst consensus is cautious with a hold-heavy rating. Key risks include equity outflows and market volatility, while opportunities lie in diversified AUM growth and innovation. The stock's performance hinges on sustaining profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
